Bank of America Initiates Coverage on Alexion Pharmaceuticals (ALXN) with a Neutral
More News related to ALXN
- Alexion to Present at Lazard Capital Markets 6th Annual Healthcare Conference
- Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of Patients With PNH at the ASH Annual Meeting
- Bernstein Initiates Coverage on Alexion Pharmaceuticals (ALXN) with at Market Perform
- Alexion to Present at Credit Suisse's 2009 Healthcare Conference
- Bank of America Initiates Coverage on Alexion Pharmaceuticals (ALXN) with a Neutral
Bank of America initiates coverage on Alexion Pharmaceuticals (Nasdaq: ALXN) with a Neutral rating. Price target $53.
To see more analyst ratings on ALXN Click Here.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and delivers drug therapies for patients with various medical conditions.
Related Categories
New CoverageStocks Mentioned
-0.46Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
